Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain

Chronic hepatitis C; Economic value

Detalhes bibliográficos
Autores: Esteban Mur, Rafael, Martín-Escudero, Victoria, Casado, Miguel Ángel, Domínguez-Hernández, Raquel
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/8729
Acesso em linha:https://hdl.handle.net/11351/8729
http://hdl.handle.net/11351/8729
Access Level:acceso abierto
Palavra-chave:Hepatitis C - Tractament
Medicaments antivírics - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
id ES_228387916ea61cdae65f30b5c03aff4e
oai_identifier_str oai:recercat.cat:11351/8729
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in SpainEsteban Mur, RafaelMartín-Escudero, VictoriaCasado, Miguel ÁngelDomínguez-Hernández, RaquelHepatitis C - TractamentMedicaments antivírics - Ús terapèuticCHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral AgentsOther subheadings::Other subheadings::/therapeutic useDISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, ChronicOther subheadings::Other subheadings::Other subheadings::/drug therapyCOMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricosOtros calificadores::Otros calificadores::/uso terapéuticoENFERMEDADES::virosis::hepatitis viral humana::hepatitis C::hepatitis C crónicaOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaChronic hepatitis C; Economic valueHepatitis C crónica; Valor económicoHepatitis C crònica; Valor econòmicBackground The treatment of chronic hepatitis C virus (HCV) with direct-acting antivirals has undergone a spectacular revolution and added significant value to healthcare systems and patients. The aim of the study was to evaluate the efficiency and value of Sofosbuvir (SOF)-based regimens for a target population of 85,959 chronic HCV patients treated in Spain during 2015–2019, compared to previous therapeutic strategies (peginterferon/ and ribavirin in double/triple therapy with telaprevir or boceprevir). Methods A previously developed lifetime Markov model was adapted to simulate the disease HCV evolution. In SOF-based regimens, all patients (100%) were treated regardless with sustained virological response (SVR) of 93–98%, obtained from real-world data. In previous therapeutic, only ≥F2 patients were treated according to clinical practice (38%) with an average SVR of 61% taken from published literature. The value was measured as clinical and economic impact in terms of avoided HCV-related mortality and liver complications; total costs and quality-adjusted life years (QALYs) applying an annual 3% discount rate. Results Compared to previous therapeutic, during lifetime, SOF-based regimens reduced decompensated cirrhosis by 89%, hepatocellular carcinoma by 77% and liver transplant by 84%, decreasing the cost associated to liver complications management in €770 million. SOF-based regimens also decreased liver-related mortality by 82%. Besides, SOF-based regimens gained 310,765/QALYs, saving €274 million (considering drugs, monitoring, and HCV management). Conclusion For Spain, SOF-based regimens offer value for HCV patients in terms of lowering HCV-related liver disease burden and generating significant cost savings for the health system, contributing to the WHO goal.The study was funded by Gilead Spain Sciences. In addition, “The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section”.Public Library of ScienceInstitut Català de la Salut[Esteban R] Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERehd, Instituto Carlos III, Barcelona, Spain. [Domínguez-Hernández R, Casado MA] Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain. [Martín-Escudero V] Gilead Sciences, Madrid, SpainVall d'Hebron Barcelona Hospital Campus202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/8729http://hdl.handle.net/11351/8729Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésPLOS ONE;17(12)https://doi.org/10.1371/journal.pone.0278544Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/87292026-05-29T05:05:01Z
dc.title.none.fl_str_mv Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
title Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
spellingShingle Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
Esteban Mur, Rafael
Hepatitis C - Tractament
Medicaments antivírics - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
title_short Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
title_full Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
title_fullStr Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
title_full_unstemmed Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
title_sort Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
dc.creator.none.fl_str_mv Esteban Mur, Rafael
Martín-Escudero, Victoria
Casado, Miguel Ángel
Domínguez-Hernández, Raquel
author Esteban Mur, Rafael
author_facet Esteban Mur, Rafael
Martín-Escudero, Victoria
Casado, Miguel Ángel
Domínguez-Hernández, Raquel
author_role author
author2 Martín-Escudero, Victoria
Casado, Miguel Ángel
Domínguez-Hernández, Raquel
author2_role author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Esteban R] Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERehd, Instituto Carlos III, Barcelona, Spain. [Domínguez-Hernández R, Casado MA] Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain. [Martín-Escudero V] Gilead Sciences, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Hepatitis C - Tractament
Medicaments antivírics - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
topic Hepatitis C - Tractament
Medicaments antivírics - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
description Chronic hepatitis C; Economic value
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/8729
http://hdl.handle.net/11351/8729
url https://hdl.handle.net/11351/8729
http://hdl.handle.net/11351/8729
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv PLOS ONE;17(12)
https://doi.org/10.1371/journal.pone.0278544
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404586063691776
score 15,811543

Registos relacionados